Clin2Atlas
AtlasPregnancy & newbornsMaternal disorders

Maternal deaths aggravated by HIV/AIDS

4Curable or preventable in mostAI-generated

Maternal deaths from HIV are largely preventable with timely ART.AI-generated

Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

What's being tested now

2000: 2 trials started2001: 4 trials started2002: 3 trials started2004: 1 trials started2007: 1 trials started2008: 3 trials started2009: 2 trials started2010: 2 trials started2011: 2 trials started2012: 6 trials started2013: 4 trials started2014: 1 trials started2015: 8 trials started2016: 5 trials started2017: 12 trials started2018: 7 trials started2019: 13 trials started2020: 13 trials started2021: 27 trials started2022: 37 trials started2023: 83 trials started2024: 113 trials started2025: 118 trials started2026: 140 trials started2000201020202026140

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 534 active Acquired Immunodeficiency Syndrome trials on Clin2 →

Where we are

AI-generated

Maternal deaths aggravated by HIV are considered curable or preventable in most cases when antiretroviral therapy (ART) is used. ART suppresses viral load, restores immunity, and reduces HIV-related maternal mortality, while also lowering mother-to-child transmission. However, access to ART remains uneven, so prevention is not guaranteed everywhere. The overall trend in HIV-related maternal deaths has been downward over recent decades, though progress varies by region and population. No specific milestone is on record for this outcome. The research pipeline is active: 530 trials have started in the last five years, including 29 phase-3 trials, and 534 trials are currently ongoing. These efforts may improve treatment options and access, but availability will depend on health systems and funding.

How does ART reduce maternal deaths in HIV-positive women?
ART suppresses the virus, restoring immune function and reducing opportunistic infections that can complicate pregnancy and delivery, thereby lowering mortality risk.
Is HIV-related maternal death always preventable?
No. While ART makes it preventable in most cases, access to timely treatment and quality maternal care is not universal, so outcomes vary.
What is the current trend in HIV-related maternal mortality?
Globally, the trend has been downward over recent decades, but progress is uneven and some regions still see high rates.
Are there new treatments being studied for this issue?
Yes. Over 500 trials have started in the last five years, including 29 phase-3 studies, with 534 trials currently active.
Does preventing mother-to-child transmission also reduce maternal deaths?
Yes. The same ART that prevents transmission also improves maternal health, so both outcomes are addressed together.

Related

Maternal hemorrhageMaternal sepsis and other maternal infectionsMaternal hypertensive disordersMaternal obstructed labor and uterine ruptureMaternal abortion and miscarriageEctopic pregnancyIndirect maternal deathsLate maternal deathsOther direct maternal disorders

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.